FindMyKOL
Clinical trialNCT00004064UnknownPhase 2Interventional

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

SponsorAltaRexEnrollment102Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Randomized phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have ovarian, fallopian tube, or peritoneal cancer.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Ottawa Regional Cancer Center - General Division

    Ottawa, Ontario, Canada

United States
  • Gynecologic Oncology Associates

    Newport Beach, California, United States

  • Lee Memorial Health System

    Fort Myers, Florida, United States

  • Walt Disney Memorial Cancer Institute

    Orlando, Florida, United States

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, United States

  • Indiana University Cancer Center

    Indianapolis, Indiana, United States

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa, United States

  • Mercy Medical Center, Inc.

    Baltimore, Maryland, United States

  • Barnes-Jewish Hospital

    St Louis, Missouri, United States

  • St. John'S Mercy Medical Center

    St Louis, Missouri, United States

  • University of Oklahoma College of Medicine

    Oklahoma City, Oklahoma, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, United States

  • Palmetto Richland Memorial Hospital

    Columbia, South Carolina, United States

  • Texas Oncology, P.A.

    Dallas, Texas, United States

  • Cancer Center, University of Virginia Hsc

    Charlottesville, Virginia, United States

  • Riverside Regional Medical Center

    Newport News, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Oregovomab
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Nov 1998
Primary completion
—
Completion
—
Last update posted
6 Nov 2013
Registered enrollment
102
Registry id
NCT00004064
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.